{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T16:23:19Z","timestamp":1783009399267,"version":"3.54.5"},"reference-count":20,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.nmd.2012.11.003","type":"journal-article","created":{"date-parts":[[2012,12,10]],"date-time":"2012-12-10T22:32:59Z","timestamp":1355178779000},"page":"176-179","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Prednisolone-sparing effect of cyclosporin A therapy for very elderly patients with myasthenia gravis"],"prefix":"10.1016","volume":"23","author":[{"given":"Seika","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiyo","family":"Shinde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-ichi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Kusaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2012.11.003_b0005","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1007\/s00415-010-5651-z","article-title":"Myasthenia gravis: a changing pattern of incidence","volume":"257","author":"Casetta","year":"2010","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2012.11.003_b0010","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJM198703193161205","article-title":"Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis","volume":"316","author":"Tindall","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2012.11.003_b0015","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1749-6632.1993.tb22937.x","article-title":"A clinical therapeutic trial of cyclosporine in myasthenia gravis","volume":"681","author":"Tindall","year":"1993","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.nmd.2012.11.003_b0020","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1468-1331.2008.02130.x","article-title":"Monitoring treatment with cyclosporine microemulsion in myasthenia gravis","volume":"15","author":"Utsugisawa","year":"2008","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nmd.2012.11.003_b0025","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/j.transproceed.2005.03.137","article-title":"Conversion from tacrolimus to cyclosporin is associated with a significant improvement of glucose metabolism in patients with new-onset diabetes mellitus after renal transplantation","volume":"37","author":"Bouchta","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1016\/j.nmd.2012.11.003_b0030","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1159\/000319172","article-title":"Two-year treatment with cyclosporine microemulsion for responder myasthenia gravis patients","volume":"64","author":"Nagane","year":"2010","journal-title":"Eur Neurol"},{"key":"10.1016\/j.nmd.2012.11.003_b0035","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: Recommendations for clinical research standards. Task force of the medical scientific advisory board of the myasthenia gravis foundation of America.","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2012.11.003_b0040","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2012.11.003_b0045","first-page":"572","article-title":"Increase in incidence of elderly-onset patients with myasthenia gravis in Nagano Prefecture","volume":"44","author":"Matsuda","year":"2005","journal-title":"Jpn Intern Med"},{"key":"10.1016\/j.nmd.2012.11.003_b0050","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1212\/01.wnl.0000176067.32186.a3","article-title":"Increasing incidence of late-onset anti-AChR antibody-seropositive myasthenia gravis","volume":"65","author":"Somnier","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2012.11.003_b0055","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1196\/annals.1254.054","article-title":"Myasthenia gravis (MG): epidemiological data and prognostic factors","volume":"998","author":"Mantegazza","year":"2003","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.nmd.2012.11.003_b0060","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1196\/annals.1405.040","article-title":"Myasthenia gravis in the elderly: Is it different?","volume":"1132","author":"Aarli","year":"2008","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.nmd.2012.11.003_b0065","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ana.410150316","article-title":"Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients","volume":"15","author":"Pascuzzi","year":"1984","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2012.11.003_b0070","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/mus.21462","article-title":"Factors associated with response to calcineurin inhibitors in myasthenia gravis","volume":"41","author":"Nagane","year":"2010","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2012.11.003_b0075","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1111\/j.1532-5415.2000.tb02635.x","article-title":"Clinical characteristics and prognosis of myasthenia gravis in older people","volume":"48","author":"Evoli","year":"2000","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.nmd.2012.11.003_b0080","first-page":"375","article-title":"Corticosteroids: a review with emphasis on complications of prolonged systemic therapy","volume":"62","author":"Truhan","year":"1989","journal-title":"Ann Allergy"},{"key":"10.1016\/j.nmd.2012.11.003_b0085","doi-asserted-by":"crossref","unstructured":"Schneider-Gold C, Gajdos P, Toyka KV, Hohlfeld RR. Corticosteroids for myasthenia gravis. Cochrane Database Syst Rev 2005:CD002828.","DOI":"10.1002\/14651858.CD002828.pub2"},{"key":"10.1016\/j.nmd.2012.11.003_b0090","first-page":"211","article-title":"Results of a one-year open trial of cyclosporine in ten patients with severe myasthenia gravis","volume":"20","author":"Goulon","year":"1988","journal-title":"Transplant Proc"},{"key":"10.1016\/j.nmd.2012.11.003_b0095","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1007\/s004150050141","article-title":"Long-term cyclosporine treatment in a group of severe myasthenia gravis patients","volume":"244","author":"Bonifati","year":"1997","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2012.11.003_b0100","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1600-0404.2005.00378.x","article-title":"Cyclosporine in the treatment of myasthenia gravis","volume":"111","author":"Lavrnic","year":"2005","journal-title":"Acta Neurol Scand"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896612006700?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896612006700?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:00:54Z","timestamp":1760774454000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896612006700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S0960896612006700"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2012.11.003","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prednisolone-sparing effect of cyclosporin A therapy for very elderly patients with myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2012.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}